What is Bexorg?
Bexorg operates at the vanguard of biotechnology, utilizing its integrated AI and whole-human brain platform to address the complexities of CNS drug development. Founded by Dr. Zvonimir Vrselja and Dr. Nenad Sestan at Yale University, the company leverages the BrainEx platform to simulate human brain responses, offering a level of clinical predictability that traditional models cannot match. By bridging the gap between computational intelligence and biological reality, Bexorg provides a robust framework for pharmaceutical companies to de-risk drug discovery pipelines. The firm maintains a strict adherence to bioethical standards, overseen by an independent board of experts, ensuring that its technological advancements remain aligned with global regulatory and ethical expectations.
How much funding has Bexorg raised?
Bexorg has raised a total of $23M across 1 funding round:
Series A
$23M
Series A (2025): $23M with participation from Starbloom Capital, Amplify Partners, Connecticut Innovations, and Little Engine Ventures
Key Investors in Bexorg
Starbloom Capital
They invest in breakthrough innovations in neuroAI, longevity, deep tech, and emerging industries. They partner with visionary founders pushing the frontiers of science, technology, and human potential.
Amplify Partners
Amplify Partners invests in early-stage companies pioneering novel applications in machine intelligence and computer science. The firm's deep domain expertise and unrivaled relationships with leading technologists, positions it uniquely with enterprise insight and the ability to serve technical founding teams.
Connecticut Innovations
Connecticut Innovations is the state's strategic venture capital arm and quasipublic investment agency, providing equity and debt financing, strategic guidance, and connections to help innovative, growing companies in the state scale, with dedicated funds for sectors like AI/quantum, climate tech, and biosciences.
What's next for Bexorg?
With this major enterprise-level funding, Bexorg is poised to scale its operational capacity and expand its collaborative research initiatives. The strategic roadmap focuses on enhancing the fidelity of its AI models and broadening the application of the BrainEx platform across diverse neurological conditions. By leveraging the expertise of its high-profile investor syndicate, the company aims to solidify its market position as the primary infrastructure provider for next-generation neuroscience research. Future growth will likely involve deepening partnerships with global pharmaceutical leaders and accelerating the validation of its predictive systems in clinical settings, ultimately aiming to shorten the development lifecycle for life-saving CNS therapeutics.
See full Bexorg company page
